Catalent Inc
NYSE:CTLT

Watchlist Manager
Catalent Inc Logo
Catalent Inc
NYSE:CTLT
Watchlist
Price: 63.5 USD 0.03% Market Closed
Market Cap: 11.5B USD
Have any thoughts about
Catalent Inc?
Write Note

Catalent Inc
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Catalent Inc
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Catalent Inc
NYSE:CTLT
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Short-Term Debt
$2B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Short-Term Debt
$205m
CAGR 3-Years
-12%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Short-Term Debt
$8.2B
CAGR 3-Years
104%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Catalent Inc
Glance View

Market Cap
11.5B USD
Industry
Pharmaceuticals
Economic Moat
None

In the intricate world of pharmaceuticals, Catalent Inc. stands out as a critical player, quietly orchestrating the development and delivery of drugs that impact lives globally. Founded in 2007, Catalent has carved a niche in the field through its commitment to advanced drug delivery technologies and supply chain services. As a contract development and manufacturing organization (CDMO), the company offers a suite of services to pharmaceutical and biotechnology firms, including drug formulation and delivery optimization, biologics development, and clinical supply services. With over 30 facilities worldwide, it acts as a pivotal partner to firms seeking to enhance the effectiveness and accessibility of their therapies without grappling with the complexities of manufacturing and logistics themselves. The crux of Catalent’s business model lies in enabling its clients to bring medical innovations to market effectively and efficiently. By leveraging its expertise in areas such as oral, injectable, and inhalable delivery forms, Catalent ensures that drugs are not only manufactured to the highest standards but are also optimized for patient adherence and effectiveness. The company earns its revenues through long-term contracts by offering continuous support from the early stages of drug development through to commercialization. Catalent drives its growth by staying ahead of industry trends, investing heavily in biologics and gene therapy, which represent high-growth areas in the pharmaceutical industry, thereby ensuring its relevance and significance in an ever-evolving healthcare landscape.

CTLT Intrinsic Value
57.58 USD
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Catalent Inc's Short-Term Debt?
Short-Term Debt
0 USD

Based on the financial report for Sep 30, 2024, Catalent Inc's Short-Term Debt amounts to 0 USD.

Back to Top